Biontech Se

This study tests an experimental mRNA vaccine (BNT166a) to see if it is safe and triggers a strong immune response against mpox (formerly monkeypox). About 310 healthy adults in African countries will receive either the vaccine or a placebo. The trial is double-blind, meaning nei…

This early-stage study tests a new antibody called BNT351 in up to 61 adults, both with and without HIV. The main goal is to check safety and how the body processes the antibody. In people with HIV, researchers will also measure if the antibody can lower the amount of virus in th…

This early-stage study tests a new drug, BNT317, for the first time in people with advanced solid tumors that have not responded to standard treatments or have no standard options. The main goal is to check the drug's safety and find the best dose. About 39 participants will rece…

This study compares a new drug, BNT324, to standard chemotherapy (docetaxel plus steroids) in men with metastatic castration-resistant prostate cancer that has progressed after prior hormone therapy. The goal is to see if BNT324 helps patients live longer and delays cancer growth…

This study tests a new drug called BNT3214 for the first time in people with advanced solid tumors. The goal is to find the safest dose and see if it can shrink tumors. About 533 adults will take part in three phases: first finding the right dose, then testing it in different can…

This study tests two experimental drugs (BNT323 and BNT327) together in people with advanced breast cancer that has spread or cannot be removed by surgery. The goal is to see if the combination can shrink tumors and control the disease. About 380 adults with various types of HER2…

This study tests whether adding the experimental drug BNT327 to standard chemotherapy helps people with a tough-to-treat type of advanced breast cancer (triple-negative) live longer without their cancer growing. About 558 participants who cannot receive current immunotherapy will…

This study tests whether a new drug called BNT327, combined with standard chemotherapy, works better than the current standard treatment (atezolizumab plus chemo) for people with extensive-stage small-cell lung cancer that hasn't been treated yet. About 621 participants will be r…

This study tests a new drug called BNT327 given together with chemotherapy for people with advanced non-small cell lung cancer who have not had treatment before. About 1260 participants will be enrolled to see if the combination shrinks tumors, delays cancer growth, and improves …

This study tests two experimental drugs, BNT326 and BNT327, together in people with advanced non-small cell lung cancer that has spread or come back. The goal is to find the best dose and see if the combination can shrink tumors and control the disease. About 420 adults will take…

This study tests an experimental drug called BNT326, alone or with other cancer treatments, in people with advanced solid tumors that have spread or come back. The goal is to find the safest dose and see if it shrinks tumors. About 980 adults will take part.

This study tests a new drug called pumitamig, alone or with other medicines, in 75 adults whose glioblastoma (a severe brain cancer) has come back after standard treatment. The goal is to see if these combinations can shrink tumors and are safe. Participants must have had prior r…

This study tests whether adding a new drug (BNT314) to an existing immunotherapy (BNT327) and chemotherapy can help people with advanced colorectal cancer that didn't respond to first-line treatment. About 482 adults with a specific type of colorectal cancer (MSS/pMMR) will recei…

This early-stage trial tests a new mRNA treatment called BNT116 for people with advanced non-small cell lung cancer. The study aims to find safe doses of BNT116 when used alone or with other cancer drugs. About 320 participants with different stages of lung cancer will take part.…

This study tests a new drug, BNT329, in people with advanced solid cancers that have a specific marker called CA19-9. The main goals are to check safety and find the best dose. About 245 participants will take part. The study also looks at whether the drug can shrink tumors or sl…

This study tests whether adding an experimental vaccine (BNT113) to a standard immunotherapy (pembrolizumab) works better than the immunotherapy alone for people with advanced head and neck cancer caused by HPV. About 350 adults with incurable, recurrent, or metastatic cancer tha…

This study tests a new drug called pumitamig combined with standard chemotherapy for people with advanced non-small cell lung cancer that has worsened after initial treatment. About 60 participants will receive the combination to see if it is safe and helps shrink tumors. The goa…

This study tests a combination of two experimental drugs, BNT324 and BNT327, in people with advanced lung cancer that has spread or come back. The goal is to see if the combination can shrink tumors and control the disease. About 594 adults with small cell or non-small cell lung …

This study is for adults with advanced solid tumors who have run out of standard treatments. It tests a new drug called BNT3212, either alone or with another drug (pumitamig), to see if it is safe and can shrink tumors. The trial is in early phases (1 and 2) and will enroll about…

This study tests a new drug called BNT323 (also known as DB-1303) against standard chemotherapy in 480 adults whose endometrial cancer has come back after previous treatment. The cancer must have a certain protein (HER2) on its surface. The main goals are to see if BNT323 slows c…

This study tests a new drug called BNT327 combined with chemotherapy in people with metastatic pancreatic cancer that has not been treated before. The goal is to see if the combination can shrink tumors and control the disease. About 105 adults will take part, and the study is cu…